Followers | 3 |
Posts | 968 |
Boards Moderated | 0 |
Alias Born | 02/07/2016 |
Saturday, September 03, 2016 1:46:33 PM
Sense checks partnerships and acquisitions,..."
This tells me that halozyme is getting ready to sell Ex-usa rights to Pegph20 a big pharma/big biotech.
"POSITION SUMMARY:
The Senior Director of Business Development plays a critical leadership role for Halozyme, leading and responsible for business development and strategy projects across the organization, including expanding the Enhanze licensing franchise and pursuing oncology related transactions. This person will be accountable for uncovering new Enhanze opportunities and developing relationships with potential partners that lead to high interest in the Enhanze platform. Additionally, this individual will be involved in searching for and achieving negotiations for potential oncology partners with the correct strategic fit for Halozyme’s pipeline and goals. The Senior Director will achieve impactful levels of inorganic revenue growth of the global Halozyme business using broad-based initiatives with the respective Halozyme functional leads. The individual in this role must also be able to fluently articulate contract structure and the biological science to potential partners.
ESSENTIAL FUNCTIONS AND RESPONSIBILITIES:
These may include, but are not limited to:
Manage drug licensing activity globally and serves as the lead negotiator with the experience and business acumen to effectively close deals. Prepares recommendations for appropriate management actions and keeps the Vice-President fully apprised of activity
Create the term sheets and leads negotiations for projects, interacting with senior members of the potential targets and partner organizations; when relationships encounter challenges under others’ leadership, steps in with rapid and successful corrective action
Support, lead, negotiate, and close deals with potential Enhanze and oncology partners, including but not limited to:
Establish initial contacts, coordinating CDA and MTA agreements,
Articulate and drive the value proposition for partner and Halozyme,
Develop and deliver external presentations and organize meetings with potential leads,
Prepare diligence materials and oversee the due diligence process,
Coordinate multiple functions at Halozyme during discussions with potential partners,
Perform deal valuation (including complex financial and market modeling), coordinate drafting of legal documents, close the deal, and integrate Alliance Management or Investor Relations at appropriate times in the partnering process.
Identify and pursue new Enhanze partners to maximize the value of Halozyme’s technology and products in a way that increases shareholder value and achieves the company’s strategic objectives
Build Enhanze brand and technology awareness with strategic publication and marketing plans, both for presentations at scientific or business conferences and publications in the research literature, which Halozyme R&D will execute
Survey the oncology landscape, approach potential partners, and close deals to further Halozyme’s oncology objectives, including but not limited to: clinical collaborations, geographic carve outs. strategic alliances, asset divestment/acquisition, and in-licensing
Sense checks partnerships and acquisitions, ensuring the most accurate estimates and calculations used for best possible Executive Team discussions and decisions
Conceive and produce strategic plans for the Board of Directors or Corporate Strategy Steering Committee as required
Maintain thorough understanding of how biotechnology companies operate and has knowledge of how companies license development stage and commercial products
Develop deep working knowledge of oncology treatments and trends, major developments and trial outcomes, and player activity in the space
Participate in external thought leader conferences and strategy meetings (e.g., drug development, emerging technologies, clinical conferences, legal updates, etc)"
Recent HALO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 10:49:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:01:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 08:03:48 PM
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis • PR Newswire (US) • 09/13/2024 05:30:00 PM
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer • PR Newswire (US) • 09/13/2024 12:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:56:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:12:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 08:05:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:16:18 PM
- Halozyme to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 11:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:03:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:11:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 08:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:59:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:31:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:57:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 08:08:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:19:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:03:09 PM
- HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:48:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2024 08:05:48 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM